A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults

Archives of Dermatology

Volumn 148, Issue 8, 2012, Pages 890-897

  Samrao, Aman ^a,b,c   Berry, Trista M ^b   Goreshi, Renato ^b   Simpson, Eric L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APREMILAST; CLOBETASOL PROPIONATE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PHOSPHODIESTERASE INHIBITOR;

ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL RESEARCH; DERMATOLOGY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FEMALE; GENETIC ANALYSIS; HUMAN; IMMUNE RESPONSE; INCIDENCE; INTENTION TO TREAT ANALYSIS; MALE; NAUSEA; PILOT STUDY; PRIORITY JOURNAL; PRURITUS; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DERMATITIS, ATOPIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INTERLEUKIN-12; MACROPHAGES; MALE; MIDDLE AGED; MONOCYTES; NAUSEA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHODIESTERASE 4 INHIBITORS; PILOT PROJECTS; PRURITUS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; THALIDOMIDE;

EID: 84865675102     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2012.812     Document Type: Article

References (28)

1. Schmitt J, Schäkel K, Schmitt N, Meurer M. Systemic treatment of severe atopic eczema: a systematic review. Acta Derm Venereol. 2007;87(2):100-111.
2. Grewe SR, Chan SC, Hanifin JM. Elevated leukocyte cyclic AMP-phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP-agonist hyporesponsiveness. J Allergy Clin Immunol. 1982;70(6):452-457.
3. Chan SC, Reifsnyder D, Beavo JA, Hanifin JM. Immunochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J Allergy Clin Immunol. 1993;91(6):1179-1188.
4. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol. 1995;105(1)(suppl):84S-88S.
5. Giustina TA, Chan SC, Thiel ML, Baker JW, Hanifin JM. Increased leukocyte sensitivity to phosphodiesterase inhibitors in atopic dermatitis: tachyphylaxis after theophylline therapy. J Allergy Clin Immunol. 1984;74(3, pt 1):252-257.
6. Souness JE, Aldous D, Sargent C. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology. 2000;47(2-3):127-162.
7. Griffiths CE, Van Leent EJ, Gilbert M, Traulsen J; Cipamyflline Study Group. Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17-butyrate cream for the treatment of atopic dermatitis. Br J Dermatol. 2002;147(2):299-307.
8. Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol. 1996;107(1):51-56.
9. Hoppmann J, Bäumer W, Galetzka C, Höfgen N, Kietzmann M, Rundfeldt C. The phosphodiesterase 4 inhibitor AWD12-281 is active in a new guinea-pig model of allergic skin inflammation predictive of human skin penetration and suppresses both Th1 and Th2 cytokines in mice. J Pharm Pharmacol. 2005;57(12):1609-1617.
10. Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs. 2007;8(5):364-372.
11. Seldon PM, Giembycz MA. Suppression of granulocyte/macrophage colony-stimulating factor release from human monocytes by cyclic AMP-elevating drugs: role of interleukin-10. Br J Pharmacol. 2001;134(1):58-67.
12. Schafer PH, Parton A, Gandhi AK, et al. Apremilast, a cAMP phosphodiesterase- 4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. Br J Pharmacol. 2010;159(4):842-855.
13. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1980;92:44-47.
14. Barbier N, Paul C, Luger T, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150(1):96-102.
15. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:13-14.
16. Vartanian K, Slottke R, Johnstone T, et al. Gene expression profiling of whole blood: comparison of target preparation methods for accurate and reproducible microarray analysis. BMC Genomics. 2009;10:2.
17. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-264.
18. Schmitt J, Schmitt N, Meurer M. Cyclosporin in the treatment of patients with atopic eczema: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2007;21(5):606-619.
19. Haeck IM, Knol MJ, Ten Berge O, van Velsen SG, de Bruin-Weller MS, Bruijnzeel- Koomen CA. Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol. 2011;64(6):1074-1084.
20. Schram ME, Roekevisch E, Leeflang MM, Bos JD, Schmitt J, Spuls PI. A randomized trial of methotrexate versus azathioprine for severe atopic eczema. J Allergy Clin Immunol. 2011;128(2):353-359.
21. Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol. 2010;185(11):6413-6419.
22. Borrelli E, Montmayeur JP, Foulkes NS, Sassone-Corsi P. Signal transduction and gene control: the cAMP pathway. Crit Rev Oncog. 1992;3(4):321-338.
23. Yang X, Liu L, Sternberg D, et al. The FLT3 internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res. 2005;65(16):7338-7347.
24. Harada H, Becknell B,Wilm M, et al. Phosphorylation and inactivation of BAD by mitochondria-anchored protein kinase A. Mol Cell. 1999;3(4):413-422.
25. Breuckmann F, von Kobyletzki G, Avermaete A, Kreuter A, Altmeyer P. Efficacy of ultraviolet A1 phototherapy on the expression of bcl-2 in atopic dermatitis and cutaneous T-cell lymphoma in vivo: a comparison study. Photodermatol Photoimmunol Photomed. 2002;18(5):217-222.
26. Yawalkar N, Uguccioni M, Schärer J, et al. Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest Dermatol. 1999;113(1):43-48.
27. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DYM. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol. 1996; 98(1):225-231.
28. Shida K, Koizumi H, Shiratori I, et al. High serum levels of additional IL-18 forms may be reciprocally correlated with IgE levels in patients with atopic dermatitis. Immunol Lett. 2001;79(3):169-175.